Curriculum Vitae

DR. EDMUND CHIN FUI MIN

Medical Lecturer
  • Department of Medicine
    Faculty of Medicine

AREAS OF EXPERTISE

  • HAEMATOLOGY
    Clinical Medicine, Haematology

ACADEMIC QUALIFICATION

  • M.MED (INTERNAL MEDICINE), UNIVERSITI MALAYA (2007), (Internal Medicine)
    Universiti Malaya (UM)
  • MBBS, UNIVERSITI MALAYA (1998), (Perubatan & Surgeri)
    Universiti Malaya (UM)

MEMBERSHIPS

  • MEMBER, MEMBER
    Since 2013 (National)
  • LIFE MEMBER, MEMBER
    Since 1995 (National)

PUBLICATIONS

Article in Journal
WoS
  1. Tay Za, K., Jackson, N., Chin, E. F. M. (2020). Tetraploid/near-tetraploid acute promyelocytic leukaemia with double (15;17) translocation. Malaysian Journal of Pathology, 42(1), 127-130.
  2. Tay Za, K., Shanmugam, H., Chin, E. F. M. (2019). A new complex translocation (8;22;21)(q22;q12;q22) in RUNX1/ RUNX1T1 acute myeloid leukaemia. Malaysian Journal of Pathology, 41(3), 333-338.
Scopus
  1. Sulaiman N.Y., Anuar N.A., Arshad N., Cheong C.S., Liong C.C., Khairullah S., Chin E.F.M., Bee P.C., Sam I.C., Iyadorai T., Gan G.G. (2023). CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country, Indian Journal of Hematology and Blood Transfusion. . doi:10.1007/s12288-023-01655-0
  2. Tay Za K., Jackson N., Chin E.F.M. (2020). Tetraploid/near-tetraploid acute promyelocytic leukaemia with double (15;17) translocation, Malaysian Journal of Pathology. 42(1), 127-130
  3. Gan G.G., Ng D.L.C., Leong Y.C., Bee P.C., Chin E.F.M., Halim H.A., Aziz T.A.H.T., Loo H., Teh A.K.H. (2019). Anxiety and depression in patients with haematological neoplasms in Malaysia, Medical Journal of Malaysia. 74(3), 191-197
  4. Tay Za K., Shanmugam H., Chin E.F.M. (2019). A new complex translocation (8;22;21)(q22;q12;q22) in RUNX1/ RUNX1T1 acute myeloid leukaemia, Malaysian Journal of Pathology. 41(3), 333-338
Others
  1. Ten, L. C., Chin, Y. M., Tai, M. C., Chin, E. F. M., Lim, Y. Y., Suthandiram, S., ... & Gan, G. G. (2017). SNP variants associated with non-Hodgkin lymphoma (NHL) correlate with human leukocyte antigen (HLA) class II expression. Scientific Reports, 7.
  2. Enteropathy-associated T-cell lymphoma: An extremely rare cause of chronic diarrhoea Liong CC 1 , Ravindran S 2 , Gnana Kumar G 3 , Chin EF 4 , Koh PS 5 , Chan WK 6 Affiliations Med J Malaysia, 2016 04;71(2):88-90.
  3. Gan GG, Leong YC, Bee PC, Chin EF, Abdul Halim H, Nadarajan VS, Teh AK (2016) Influence of genetic polymorphisms of cytokine genes in the outcome of HLA-matched allogeneic stem cell transplantation in a South East Asian population. Cytokine. 78,55-61
  4. Complementary and alternative medicine use in patients with hematological cancers in Malaysia G. G. Gan, Y. C. Leong, P. C. Bee, E. Chin & A. K. H. Teh Supportive Care in Cancer volume 23, pages2399 2406 (2015)
  5. Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients.
  6. Acquired Factor VIII Inhibitors: Three Cases. Turk J. Haematol 2013; 30: 76-80.
  7. Helicobacter pylori infection in chronic immune thrombocytopenic purpura patients in Malaysia.
  8. An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia.
  9. Myeloid Sarcoma: An Unusual Presentation of Acute Promyelocytic Leukemia Causing Spinal Cord Compression
  10. Quality of life after haematopoietic stem cell transplantation in a multiracial population Bee PC , Gan GG , Sangkar VJ , Haris AR , Chin E Med J Malaysia, 2011 Dec;66(5):451-5.
  11. R. Karunakaran, H.A. Halim, K.P. Ng, Y.A. Hanifah, E. Chin, F.L. Jaafar, S. Abubakar 2011. Tsukumurella tyrosinosolvens intravascular catheter-related bacteremia in a haematology patient: a case report
  12. Adult Allogeneic Haematopoeitic Stem Cell Transplantation: A Single Centre Experience in Malaysia; Gan GG, Zakaria Z, Sangkar JV, Haris AR, Bee PC, Chin E, Teh A: Medical Journal of Malaysia 2008; 63 (4):281-7
Other Publications
  1. When non-Hodgkin's lymphoma returns Dr. Edmund Chin - Mass Media(Newspaper,Radio,Tv,Popular Magazine)

RESEARCH PROJECT

National
  1. 2020 - 2028, Novartis Corporation (M) Sdn. Bhd.
    A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) ( Co-Researcher)
  2. 2022 - 2025, NS Pharma, Inc
    A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 versus Best Available Therapy in Subjects with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/ L) ( Principal Investigator(PI))
  3. 2012 - 2014, Geran Penyelidikan Universiti Malaya (UMRG)
    polymorphisms in DNA repair genes and risk of Non Hodgkin lymphoma ( Principal Investigator(PI))
Private
  1. 2023 - 2027, Novartis Corporation (Malaysia) Sdn. Bhd.
    A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE ( Co-Researcher)
  2. 2022 - 2025, Novartis Corporation (Malaysia) Sdn Bhd
    A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features ( Principal Investigator(PI))
International
  1. 2022 - 2027, CONSTELLATION PHARMACEUTICAL, INC
    A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients ( Co-Researcher)
  2. 2019 - 2024, Monash University
    Asia Pacific Myeloma and related diseases registry ( Co-Researcher)
  3. 2023 - 2024, Janssen Research & Development LLC
    EFFICACY AND SAFETY OF M281 IN ADULTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH A LONG-TERM OPEN-LABEL EXTENSION ( Co-Researcher)
  4. 2022 - 2023, AstraZeneca Sdn. Bhd.
    A Multicenter Retrospective Study To Understand The Clinical Characteristics, Treatment Pathway And Resource Utilization For Patients With Chronic Lymphocytic Leukemia (CLL). ( Co-Researcher)
  5. 2019 - 2022, INTERNATIONAL MYELOMA FOUNDATION
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)
  6. 2019 - 2022, INTERNATIONAL MYELOMA FOUNDATION
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)
  7. 2019 - 2021, Private Funding
    A Phase 3, Randomized, Multicentre, Open-label, Controlled Study to evaluate the efficacy and safety of APL-2 in Patients with Paroxysmal Nocturnal Haemoglobinuria ( Consultant)
  8. 2020 - 2021, Private Funding
    An Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) ( Consultant)
  9. 2016 - 2019, Private Funding
    A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin s lymphoma (iNHL) CHRONOS-3 ( Principal Investigator(PI))
  10. 2011 - 2014, Pharmaceutical
    A two-stage phase III, international, multi- center, randomized. controlled, open-label study to investigate the pharmacokinetics, efficacy and safety of rituximab SC in combination with CHOP or CVP versus rituximab IV in combination with CHOP or CVP in patients with previously untreated follicular lymphoma followed by maintenance treatment with either rituximab SC or rituximab IV. ( Principal Investigator(PI))

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2023) Examiner of Eop Stage 3.1 Class of 2020/2025 Session 2023/2024 (Cohort 2021): Posting A, University, (Internal Examiner)
  2. (2023) Pemeriksa Sempena Peperiksaan Klinikal Program Sarjana Perubatan Dalaman (Bahagian Ii) Sesi Oktober/November 2023 (Uitm / UM / Usm / UKM / UPM / UIAM), National, (External Examiner)
  3. (2023) Pemeriksa Semasa Kertas Osce Bagi Peperiksaan Tambahan Peringkat 1 (Barrier Assessment) Sarjana Muda Perubatan dan Sarjana Muda Pembedahan (MBBS) Sesi 2022/2023, University, (Internal Examiner)
  4. (2023) Examiner of Eop Stage 3.1 Class of 2019/2024 Session 2022/2023 (Cohort 2020): Supplementary, University, (Internal Examiner)
  5. (2023) Examiner of Eop Stage 3.3 Cohort 2018 : Posting K (Stream 2 ), University, (Internal Examiner)
  6. (2023) Examiner of Eop Stage 3.1 Class of 2020/2025 Session 2022/2023 (Cohort 2020): Posting C, University, (Internal Examiner)
  7. (2023) Pemeriksa Bagi Peperiksaan Teori (Bahagian Ii) Program Master Perubatan (Perubatan Dalaman) Sesi April 2023, National, (External Examiner)
  8. (2023) Examiner of Eop Stage 3.3 Cohort 2018 : Posting I (Stream 4 ), University, (Internal Examiner)
  9. (2022) Examiner for Osce Part 2- Barrier Assessment, University, (Internal Examiner)
  10. (2022) Examiner for Osce Part 2- Barrier Assessment, University, (Internal Examiner)
  11. (2022) Examiner for Part 2 Theory Paper for Masters in Internal Medicine September 2022, University, (Internal Examiner)
  12. (2022) Examiner for Part 2 Theory Paper for Masters in Internal Medicine September 2022, National, (External Examiner)
  13. (2022) Identification of Microrna and Mrnas Associated With R-Chop Chemotherapy Resistance and Disease Progression in Patients With Diffuse Large B-Cell Lymphoma, University, (Internal Assessor)
  14. (2022) Identification of Microrna and Mrnas Associated With R-Chop Chemotherapy Resistance and Disease Progression in Patients With Diffuse Large B-Cell Lymphoma, University, (Internal Assessor)
  15. (2022) Masters in Internal Medicine Research Project Proposal Presentation, University, (Internal Assessor)
  16. (2022) Class of 2019/2024 Session 2021/2022 (Cohort 2019) : Posting B Examiner of Eop Stage 3.1, University, (Internal Examiner)
  17. (2021) Masters in Internal Medicine 2nd Research Project Progress, University, (Internal Assessor)
  18. (2021) Part 1 Clinical (Short Cases) for Masters in Internal Medicine, National, (External Examiner)
  19. (2021) End of Posting Exam Stage 3.1; Class of 2018/2023 : Posting C, University, (Internal Examiner)
  20. (2021) End of Posting Exam Stage 3.1 ;Class of 2018/2023 : Posting D, University, (Internal Examiner)
  21. (2021) Masters in Internal Medicine 1st Research Project Progress, University, (Internal Assessor)
  22. (2021) Peperiksaan Peringka T 2 Sarjana Muda Perubatan dan Sarjana Muda Pembedahan (MBBS) Sesi 2020/2021- Kertas Osce, University, (Internal Examiner)
  23. (2021) Masters of Internal Medicine Part 2; May 2021, University, (Internal Examiner)
  24. (2021) Examiner of Eop Stage 3.3 ;Class of 2016/2021 : Posting K, University, (Internal Examiner)
  25. (2021) Masters in Internal Medicine Research Project Proposal, University, (Internal Assessor)
  26. (2021) Masters in Internal Medicine Final Thesis Progress Presentation, University, (Internal Assessor)
Contribution to event
  1. (2023) Chairperson of a Talk On Diagnosis and Management of Ifis in The Immunocompromised, University, (Panelist/Moderator)
  2. (2022) Live Webinar Series : Breakfast @ Umhealth, University, (Panelist/Moderator)
  3. (2022) Approach to Polycythaemia - Speaker, National, (Panelist/Moderator)
  4. (2021) Moderator/ Masterclass in Systemic Cancer Therapy(Msct) 2021, National, (Panelist/Moderator)
Media appearance
  1. (2023) Rayuan Pesakit Talasemia Buat Bakal Pengantin Buletin Tv9, National, (Interview)
  2. (2022) Mypact On The Go: Haematologist X Orthopaedics Bone Pain? Can it Be a Sign for Multiple Myeloma?, National, (Host)

SUPERVISION

Postgraduate Student
  1. (2023) -, CHEW HAN JIA
  2. (2021) -, GIRISHRAJ RAJANDRAN
  3. (2018) -, MUHAMMAD FAIZ BIN CHE JUSOH
  4. (2017) -, LOO WAI YANG
  5. (2015) USE OF DRUGS AND TRADITIONAL AND COMPLEMENTARY MEDICATION (TCM) WHICH MAY AFFECT BLEEDING AMONG PATIENTS PLANNED FOR SKIN SURGERY IN A DERMATOLOGY UNIT IN MALAYSIA., KAUSALYAA A/P RADHA
  6. (2014) -, NG RONG XIANG
  7. (2012) -, LIM SHU XIAN
  8. (2012) -, NORAZLINDA BINTI ROZALI
  9. (2010) -, ALBERT HING (WONG)

TEACHING

Master
  1. (2023) NA - Mmed-Master in Internal Medicine
  2. (2022) mmed - Master in Internal Medicine
  3. (2021) - - Master of Internal Medicine(Mmed)
Bachelor
  1. (2023) NA - Ummp Stage 2 Cohort 2022
  2. (2023) NA - Ummp Stage 3.1 Cohort 2019
  3. (2023) NA - Ummp Stage 3.3 Cohort 2018
  4. (2022) ummp - Ummp Stage 2 Cohort 2020
  5. (2022) ummp - Ummp Stage 3.1 Cohort 2019
  6. (2022) ummp - Ummp Stage 3.3 Cohort 2017
  7. (2021) MIA 2001 - Stage 2
  8. (2021) - - Universiti Malaya Medical Programme (Ummp) 3.3
  9. (2021) MIA 2001 - Universiti Malaya Medical Programme (Ummp) Stage 2

COURSE ATTENDED

Internal / External Course
EXTERNAL COURSE
  1. BENGKEL GOOD CLINICAL PRACTICE, Pusat Perubatan Untiversiti Malaya (24 Jun 2008 - 26 Jun 2008)
CONFERENCE
  1. 38TH EBMT ANNUAL MEETING 2012 IN GENEVA, Geneva (31 Mar 2012 - 05 Apr 2012)
  2. CENTER OF EXCELLENCE(COE) FOR MULTIPLE MYELOMA, HOSPITAL UNIVERSITARIO DE SALAMANCA, SALAMANCA, SPAIN, 19-20 SEPTEMBER 2011, Hospital Universitario De Salamanca, Salamanca , Spain (18 Sep 2011 - 21 Sep 2011)
  3. 18TH CONGRESS OF EHA 2013, Stockholmsmassan, Massvagen 1, Alvsjo, Stockholm, Sweden (12 Jun 2013 - 17 Jun 2013)
  4. 5TH CENTRE OF EXCELLENCE IN HEMATOLOGICAL MALIGNANCIES, National University of Singapore and Singapore General Hospital (19 Jul 2018 - 21 Jul 2018)
  5. 16TH MALAYSIAN SOCIETY OF HAEMATOLOGY ANNUAL SCIENTIFIC MEETING (MSH 2019), Kinta Riverfront Hotel and Suites Ipoh Perak (11 Apr 2019 - 13 Apr 2019)
  6. 17TH MALAYSIAN SOCIETY OF HAEMATOLOGY ANNUAL SCIENTIFIC MEETING(MSH 2020), Shangri-La Hotel, Kuala Lumpur, Malaysia (10 Sep 2020 - 12 Sep 2020)
  7. 12TH CONGRESS OF THE ASIAN-PACIFIC SOCIETY OF THROMBOSIS AND HEMOSTASIS, Borneo Convention Centre Kuching, Bcck, Kuching, Sarawak, Malaysia (19 Oct 2023 - 21 Oct 2023)